法国2015年轮状病毒疫苗接种的获益-风险分析
该分析比较法国2015年轮状病毒疫苗接种所预防的轮状病毒胃肠炎住院与疫苗所致肠套叠住院。在9.5%接种覆盖率下,估计每年预防1074例住院和1.4例死亡,并导致5.0例住院和0.005例死亡;住院获益-风险比为214,死亡为273。结论认为法国获益-风险比与其他欧洲国家相似。
要点
- 9.5%接种覆盖率下,轮状病毒疫苗每年估计预防1074例轮状病毒胃肠炎住院和1.4例死亡。
- 同一覆盖率下,估计每年导致5.0例肠套叠住院和0.005例死亡。
- 住院获益-风险比为214,死亡获益-风险比为273。
核心结论
- 法国的轮状病毒疫苗接种获益-风险比与其他欧洲国家相似。
研究设计与样本
- 研究比较法国轮状病毒疫苗接种所预防的轮状病毒胃肠炎住院数与疫苗所致肠套叠住院数。
- 分析基于法国2015年估计的9.5%接种覆盖率,并模拟92%接种覆盖率下Rotarix接种的情形。
主要发现
- 9.5%覆盖率下,估计每年预防1074例轮状病毒胃肠炎住院(2.5th-97.5th:810-1378)和1.4例死亡(2.5th-97.5th:1.2-1.6)。
- 9.5%覆盖率下,估计每年导致5.0例肠套叠住院(2.5th-97.5th:3.2-7.7)和0.005例死亡(2.5th-97.5th:0.001-0.015)。
- 住院获益-风险比为214(2.5th-97.5th:128-362),死亡获益-风险比为273(2.5th-97.5th:89-1228)。
- 假设92%覆盖率下,Rotarix接种每年避免10459例轮状病毒胃肠炎住院(2.5th-97.5th:7702-13498)并导致47.0例肠套叠住院(2.5th-97.5th:25.1-81.4)。
- 92%覆盖率下,每年预防13.7例死亡(2.5th-97.5th:11.1-15.2)并导致0.05例死亡(2.5th-97.5th:0.01-0.15)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IntroductionTwo vaccines available for protection against rotavirus gastroenteritis (RVGE), Rotarix and RotaTeq, have contributed to a large decrease in the incidence of paediatric diarrhoea in countries where they have been used. However, they have also led to a small increase in the risk of intussusception. Methods: We compare the number of prevented hospitalisations for RVGE to the number of vaccine-induced hospitalised intussusceptions in France. Results: With 9.5% coverage (French 2015 estimation), vaccination was estimated to prevent, annually, a median of 1,074 hospitalisations (2.5th and 97.5th percentiles (2.5th-97.5th): 810-1,378) and 1.4 deaths (2.5th-97.5th: 1.2-1.6) from RVGE. It was also estimated to cause, annually, 5.0 hospitalisations (2.5th-97.5th: 3.2-7.7) and 0.005 deaths (2.5th-97.5th: 0.001-0.015) from intussusception. The benefit-risk ratio is therefore 214 (2.5th-97.5th: 128-362) for hospitalisations and 273 (2.5th-97.5th: 89-1,228) for deaths. Under a hypothetical 92% coverage, rotavirus vaccination with Rotarix would avoid 10,459 (2.5th-97.5th: 7,702-13,498) hospitalisations for RVGE and induce 47.0 (2.5th-97.5th: 25.1-81.4) hospitalisations for intussusception annually, thereby preventing 13.7 (2.5th-97.5th: 11.1-15.2) deaths and inducing 0.05 (2.5th-97.5th: 0.01-0.15) deaths. Conclusion: The benefit-risk ratio in France is similar to that of other European countries.
引用
- Lamrani A, Tubert-Bitter P, Hill C, et al. A benefit-risk analysis of rotavirus vaccination, France, 2015. Euro Surveill. 2017. PMID: 29258644. doi:10.2807/1560-7917.ES.2017.22.50.17-00041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。